Celcuity LLC Net Income Over Time
| CELC Stock | USD 106.78 1.07 1.01% |
With this module, investors can use any or all of fundamental ratio historical patterns as a complementary method for asset selection as well as a tool for deciding entry and exit points. Many technical investors use fundamentals to limit their universe of possible portfolio assets.
Check out Celcuity LLC Performance and Celcuity LLC Correlation. Will Biotechnology sector continue expanding? Could Celcuity diversify its offerings? Factors like these will boost the valuation of Celcuity LLC. Projected growth potential of Celcuity fundamentally drives upward valuation adjustments. Accurate valuation requires analyzing both current fundamentals and future growth trajectories. Every Celcuity LLC data point contributes insight, yet successful analysis hinges on identifying the most consequential variables.
The market value of Celcuity LLC is measured differently than its book value, which is the value of Celcuity that is recorded on the company's balance sheet. Investors also form their own opinion of Celcuity LLC's value that differs from its market value or its book value, called intrinsic value, which is Celcuity LLC's true underlying value. Seasoned market participants apply comprehensive analytical frameworks to derive fundamental worth and identify mispriced opportunities. Because Celcuity LLC's market value can be influenced by many factors that don't directly affect Celcuity LLC's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
It's important to distinguish between Celcuity LLC's intrinsic value and market price, which are calculated using different methodologies. Investment decisions regarding Celcuity LLC should consider multiple factors including financial performance, growth metrics, competitive position, and professional analysis. Meanwhile, Celcuity LLC's quoted price indicates the marketplace figure where supply meets demand through bilateral consent.
Cross Equities Net Income Analysis
Compare Celcuity LLC and related stocks such as CG Oncology Common, Ascentage Pharma, and Centessa Pharmaceuticals Net Income Over Time
Select Fundamental| 2010 | 2011 | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| CGON | (12.8 M) | (12.8 M) | (12.8 M) | (12.8 M) | (12.8 M) | (12.8 M) | (12.8 M) | (12.8 M) | (12.8 M) | (12.8 M) | (12.8 M) | (12.8 M) | (35.4 M) | (48.6 M) | (88 M) | (79.2 M) | (75.3 M) |
| AAPG | (107.8 M) | (107.8 M) | (107.8 M) | (107.8 M) | (107.8 M) | (107.8 M) | (107.8 M) | (118.5 M) | (345.3 M) | (1.5 B) | (677.6 M) | (782.4 M) | (882.9 M) | (925.6 M) | (405.4 M) | (364.9 M) | (383.1 M) |
| CNTA | (5.3 M) | (5.3 M) | (5.3 M) | (5.3 M) | (5.3 M) | (5.3 M) | (5.3 M) | (5.3 M) | (5.3 M) | (5.3 M) | (10.7 M) | (381.9 M) | (216.2 M) | (151.1 M) | (235.8 M) | (212.2 M) | (222.8 M) |
| APGE | (39.8 M) | (39.8 M) | (39.8 M) | (39.8 M) | (39.8 M) | (39.8 M) | (39.8 M) | (39.8 M) | (39.8 M) | (39.8 M) | (39.8 M) | (39.8 M) | (39.8 M) | (84 M) | (182.1 M) | (163.9 M) | (155.7 M) |
| XENE | (12 M) | (12 M) | (4.3 M) | 12 M | 13 M | (15.8 M) | (23 M) | (30.7 M) | (34.5 M) | (41.6 M) | (28.8 M) | (78.9 M) | (125.4 M) | (182.4 M) | (234.3 M) | (210.9 M) | (200.4 M) |
| RARE | (6.8 M) | (6.8 M) | (16.3 M) | (35.1 M) | (59.8 M) | (145.6 M) | (245.9 M) | (302.1 M) | (197.6 M) | (402.7 M) | (186.6 M) | (454 M) | (707.4 M) | (606.6 M) | (569.2 M) | (575 M) | (546.2 M) |
| TVTX | (18.3 K) | (14.8 K) | (30.3 M) | (33.8 M) | (110.9 M) | 117.2 M | (47.9 M) | (59.7 M) | (102.7 M) | (146.4 M) | (169.4 M) | (180.1 M) | (278.5 M) | (111.4 M) | (321.5 M) | (289.4 M) | (274.9 M) |
| LEGN | 9.4 M | 9.4 M | 9.4 M | 9.4 M | 9.4 M | 9.4 M | 9.4 M | 9.4 M | (2.8 M) | (101.6 M) | (266.4 M) | (403.6 M) | (446.3 M) | (518.3 M) | (177 M) | (159.3 M) | (167.3 M) |
| IRON | (40.8 M) | (40.8 M) | (40.8 M) | (40.8 M) | (40.8 M) | (40.8 M) | (40.8 M) | (40.8 M) | (40.8 M) | (40.8 M) | (40.8 M) | (36 M) | (46.1 M) | (76.4 M) | (109.4 M) | (98.4 M) | (103.3 M) |
| ZLAB | (18 M) | (18 M) | (18 M) | (18 M) | (18 M) | (18 M) | (37.5 M) | (50.4 M) | (139.1 M) | (183.4 M) | (268.9 M) | (704.5 M) | (443.3 M) | (334.6 M) | (257.1 M) | (231.4 M) | (243 M) |
Celcuity LLC and related stocks such as CG Oncology Common, Ascentage Pharma, and Centessa Pharmaceuticals Net Income description
Net income is one of the most important fundamental items in finance. It plays a large role in Celcuity LLC financial statement analysis. It represents the amount of money remaining after all of Celcuity LLC operating expenses, interest, taxes and preferred stock dividends have been deducted from a company total revenue.My Equities
My Current Equities and Potential Positions
| Celcuity LLC | CELC |
Specialization | Health Care, Pharmaceuticals, Biotechnology & Life Sciences |
| Business Address | 16305 36th Avenue |
| Exchange | NASDAQ Exchange |
USD 106.78
Check out Celcuity LLC Performance and Celcuity LLC Correlation. For information on how to trade Celcuity Stock refer to our How to Trade Celcuity Stock guide.You can also try the Idea Analyzer module to analyze all characteristics, volatility and risk-adjusted return of Macroaxis ideas.
Celcuity LLC technical stock analysis exercises models and trading practices based on price and volume transformations, such as the moving averages, relative strength index, regressions, price and return correlations, business cycles, stock market cycles, or different charting patterns.